LY3009120   Click here for help

GtoPdb Ligand ID: 8943

Synonyms: LY-3009120
PDB Ligand
Compound class: Synthetic organic
Comment: LY3009120 is a pan-RAF kinase and RAF dimer inhibitor [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 3
Rotatable bonds 8
Topological polar surface area 91.83
Molecular weight 424.24
XLogP 4.63
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES CNc1ncc2c(n1)nc(c(c2)c1cc(NC(=O)NCCC(C)(C)C)c(cc1C)F)C
Isomeric SMILES CNc1ncc2c(n1)nc(c(c2)c1cc(NC(=O)NCCC(C)(C)C)c(cc1C)F)C
InChI InChI=1S/C23H29FN6O/c1-13-9-18(24)19(29-22(31)26-8-7-23(3,4)5)11-16(13)17-10-15-12-27-21(25-6)30-20(15)28-14(17)2/h9-12H,7-8H2,1-6H3,(H2,26,29,31)(H,25,27,28,30)
No information available.
Summary of Clinical Use Click here for help
LY3009120 is being assessed in a Phase 1 clinical trial (NCT02014116) for its potential anti-cancer action.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02014116 A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body Phase 1 Interventional Eli Lilly and Company